Autotaxin inhibition mitigates chronic kidney disease by reducing renal tubular lysosome–mitochondria stress and suppressing fibroblast activation
Kidney Research and Clinical Practice · 05.11.2026
DOI: 10.23876/j.krcp.26.212 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney Research and Clinical Practice, online erschienen am 05.11.2026. Verfasst von Seong Woo Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Republic of Korea.
Abstract (Originalsprache)
Background
Autotaxin (ATX) catalyzes lysophosphatidic acid (LPA) production and has been implicated in fibrotic diseases. However, its role in chronic kidney disease (CKD), particularly its spatial distribution and association with tubular injury, and its contribution to cellular remodeling remains unclear. This study investigated the therapeutic effects and potential mechanisms of autotaxin inhibition (ATXi) in experimental CKD.
Methods
ATX expression and cell type-specific Enpp2 expression were evaluated in CKD mouse models induced by folic acid (FA) or an adenine diet. In a separate intervention study, FA-induced CKD mice were treated with ATXi or vehicle. Renal function, fibrosis, tubular injury, lipid accumulation, and mitochondrial and lysosomal alterations were assessed. In vitro, NRK-49F fibroblasts were treated with transforming growth factor beta (TGF-β) with or without ATXi.
Results
ATX expression was increased in CKD kidneys and was predominantly localized to the tubulointerstitium. ATXi treatment significantly attenuated blood urea nitrogen elevation and tended to reduce cystatin C levels, along with improving tubular injury and interstitial fibrosis, collagen deposition and alpha-smooth muscle actin expression. Renal lipid accumulation and increased LPA receptor mRNA expression observed in CKD were also reduced following ATXi treatment. In addition, ATXi ameliorated tubular mitochondrial structural damage and lysosomal stress. Furthermore, ATXi suppressed TGF-β-induced fibroblast activation and proliferation in vitro.
Conclusion
Pharmacologic inhibition of ATX attenuated CKD, accompanied by improvements in mitochondrial structural abnormalities, modulation of lysosome-associated responses, and suppression of fibroblast activation, thereby reducing tubular injury and renal fibrosis. These findings support a pathogenic role of the ATX-LPA axis in CKD and highlight ATXi as a potential therapeutic target.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Republic of Korea.
- Departments of Medicine and Biomedical Science, Graduate School, Soonchunhyang University, Cheonan, Republic of Korea.
- Ochang Bio & Environmental Research Institute, Korea Basic Science Institute, Cheongju, Republic of Korea.
- Department of Pathology, Soonchunhyang University Cheonan Hospital, Cheonan, Republic of Korea.
- Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Republic of Korea. eylee@sch.ac.kr.
- Departments of Medicine and Biomedical Science, Graduate School, Soonchunhyang University, Cheonan, Republic of Korea. eylee@sch.ac.kr.
Zitieren
APA
Lee, S. W., Son, S. S., Na, K. H., Park, S. H., Lee, J., Lee, S. H., Lee, J. H., & Lee, E. Y. (2026). Autotaxin inhibition mitigates chronic kidney disease by reducing renal tubular lysosome–mitochondria stress and suppressing fibroblast activation. Kidney Research and Clinical Practice. https://doi.org/10.23876/j.krcp.26.212
Vancouver
Lee SW, Son SS, Na KH, Park SH, Lee J, Lee SH, et al. Autotaxin inhibition mitigates chronic kidney disease by reducing renal tubular lysosome–mitochondria stress and suppressing fibroblast activation. Kidney Research and Clinical Practice. 2026. doi:10.23876/j.krcp.26.212
BibTeX
@article{Lee2026,
author = {Lee, Seong Woo and Son, Seung Seob and Na, Kyung Hoon and Park, Se Hun and Lee, Jina and Lee, Sang Hee and Lee, Ji-Hye and Lee, Eun Young},
title = {Autotaxin inhibition mitigates chronic kidney disease by reducing renal tubular lysosome–mitochondria stress and suppressing fibroblast activation},
journal = {Kidney Research and Clinical Practice},
year = {2026},
doi = {10.23876/j.krcp.26.212}
}
EUVIMED